Net Loss per Common Share (Tables)

6 Months Ended

Jun. 30, 2025

Earnings Per Share [Abstract]

Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders

The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:

	June 30,
	2025		2024*
Stock options outstanding		12,717,406		6,956,497
Restricted stock units outstanding		1,942,478		3,053,833
Shares reserved for future issuance		4,987,940		1,578,783
Apexigen replacement warrants		1,003,191		1,003,191
Employee stock purchase plan		653,777		615,603
Total		21,304,792		13,207,907

*Pre-Funded Warrant Shares of 1,611,215 shares are included in the computation of basic and diluted net loss per common share for the three and six months ended June 30, 2024 as the Pre-Funded Warrants were issuable for nominal consideration.